



Zymeworks Inc. announces closing of \$1.3 million financing and addition to the board of directors

Vancouver, Canada, March 3, 2008 – Zymeworks Inc. today announced that it has closed a \$1.3 million round of financing from private investors. Zymeworks has now successfully raised \$3.5 million from angel investors in three rounds of financing. In conjunction with the financing, the Company has also announced that Mr. Amos Michelson will join the Company's Board of Directors.

“Completing this financing represents an important funding milestone,” stated Dr. Ali Tehrani, President & CEO of Zymeworks Inc. “This investment will facilitate the further development of the ZymeCAD™ platform and accelerate development activities towards our protein-therapeutics pipeline.”

Zymeworks is also delighted to add Amos to its Board of Directors. “We look forward to Amos’ contribution derived from his experience and proven track record. As a seasoned CEO and entrepreneur, Amos has experience developing and executing successful strategic plans, first hand knowledge of capital markets and an extensive track record of leading companies at various stages.” One of Mr. Michelson’s recent ventures involved leading Creo Inc. from a market value of \$10 million to a post-IPO value of \$2.5 billion within nine years.

About Zymeworks Inc.

Zymeworks is a computational biotechnology company that combines proprietary molecular simulation technology with high performance computing to research and develop industrial enzymes and protein therapeutics. Zymeworks uses its proprietary ZymeCAD™ molecular simulation platform and world-class team of protein engineers to alter enzyme substrate specificity and antibody-binding affinities. The ZymeCAD™ platform creates a highly detailed computational modeling environment for accurate and predictive semi-rational protein engineering. This detailed physical and chemical insight is used to address the specific needs of Zymeworks’ customers and advance its protein-therapeutics pipeline.

Mr. Amos Michelson was the CEO of Creo Inc. from 1995 to 2005. He joined Creo in 1991 and, prior to his appointment as CEO, served in senior positions including Vice President Business Strategy, Managing Director, and Chairman of the Board. Before joining Creo, Amos was CEO of Opal, Inc., a semiconductor equipment company, and COO of Optrotech Ltd., a developer and manufacturer of optical and imaging systems for the electronics industry. Amos is a past member of the British Columbia Premier’s Technology Council. In 1999, together with Dan Gelbart (co-founder of Creo Inc.), he was named an Ernst & Young Entrepreneur Of The Year® and in 2005 was recognized as the British Columbia Technology Industry Association’s “Person of the Year”. Amos holds an MBA from the Stanford Business School and a BSEE from the Technion, Israel Institute of Technology, and serves on the boards of Genologics Life Science Software Inc., Sirius Genomics Inc., Cogent Health Solutions and multiple other start-ups.

For further information, contact Dr. Ali Tehrani, President & CEO of Zymeworks Inc. at:

Tel: 604-678-1388

E-mail: info@zymeworks.com

Website: www.zymeworks.com